Reset Pharmaceuticals

Reset Pharmaceuticals is a biotechnology startup founded in 2020, dedicated to advancing novel psychedelic medicines to improve mental health in individuals with life-threatening illnesses, particularly cancer. The company's lead program revolves around psilocybin in conjunction with psychotherapy, aiming to address demoralization, anxiety, and depression in cancer patients. Reset Pharma has garnered significant support, having secured a $11.10M Series A investment on 16 February 2022, with key participation from Negev Capital, PsyMed Ventures, and Ayuh Ventures. The company has positioned itself with a highly experienced biotech development team and boasts a Scientific Advisory Board comprising leading experts in psychiatry, oncology, and psychedelics. Reset Pharmaceuticals operates at the intersection of biotechnology and healthcare, pioneering innovative approaches to address critical mental health needs in individuals facing life-threatening illnesses.